The clinical pedigree of the scaffold is difficult to overstate. Celecoxib, the archetypal COX-2 selective anti-inflammatory, ruxolitinib, the JAK inhibitor that transformed myelofibrosis care, and crizotinib, the ALK inhibitor that reshaped treatment of ALK-positive lung cancer, all carry the pyrazole core. According to the review, more than 30 pyrazole-containing drugs have been approved by the U.S. Food and Drug Administration since 2011, targeting diseases as varied as cancer, cystic fibrosis, HIV, rheumatoid arthritis and hereditary angioedema. Recent additions to that list include lenacapavir, a long-acting HIV capsid inhibitor; berotralstat, a kallikrein inhibitor for hereditary angioedema; and pirtobrutinib, a non-covalent BTK inhibitor designed for patients who have progressed on covalent predecessors. Each new approval reinforces the argument that the ring’s electronic configuration, hydrogen-bonding capability and conformational mimicry give medicinal chemists an unusually versatile handle on biological targets.

What explains this durability at the molecular level? The review devotes careful attention to the structural logic of the scaffold. Pyrazole’s aromaticity arises from delocalized pi-electrons across the five-membered ring, and the two nitrogen atoms exert a profound influence on polarity, dipole moment and reactivity. The N-H group acts as a hydrogen bond donor while the adjacent pyridine-like nitrogen serves as an acceptor, allowing the ring to engage enzymatic pockets in multiple orientations. Electrophilic substitution proceeds preferentially at C-4, while nucleophilic substitution favours C-3 and C-5, and tautomerism between the nitrogens adds a further layer of chemical adaptability. Because the ring can also serve as a bio-isostere for other aromatic systems, substituting pyrazole into a lead molecule often improves pharmacokinetic and pharmacodynamic behaviour simultaneously, a rare combination in scaffold-hopping exercises.

The heart of the review is its catalogue of newly synthesized derivatives and their measured activities, and the numbers are striking. Anwer and colleagues reported azobenzene-linked pyrazole-pyrimidine hybrids in which the leading compound achieved sub-micromolar cytotoxicity across four tumour cell lines, with IC50 values between 5.12 and 6.77 micromolar, while potently inhibiting VEGFR-2 at 0.90 micromolar and the resistant EGFR T790M mutant at 0.25 micromolar, outperforming erlotinib and matching sorafenib. Xu and co-workers fused pyrazole onto the natural product matrine, producing a derivative that killed Huh-7 hepatocellular carcinoma cells at 5.92 micromolar by inducing apoptosis, arresting cells in G0/G1 and suppressing JAK/STAT signalling in a dose-dependent manner. These are not incremental tweaks to known chemotypes; they represent deliberate re-engineering of how the scaffold engages intracellular machinery.

Selectivity, the perennial challenge of oncology drug design, emerges as a defining theme of the 2025-2026 cohort. Kou and colleagues built dihydropyrimidinone-pyrazole hybrids targeting the SHP2 phosphatase and achieved selectivity indices as high as 475.44 against MIA PaCa-2 pancreatic cancer cells relative to normal cells, meaning the compounds are hundreds of times more toxic to tumours than to healthy tissue. Fadaly’s group introduced oxime and nitrate moieties that enable covalent docking to the Cys797 residue of the double-mutant EGFR L858R/T790M, yielding IC50 values of 0.031 to 0.076 micromolar and selectivity windows comparable to osimertinib, the clinical standard for this mutation. Meanwhile, Abd El-Karim’s benzofuran-pyrazole hybrids displayed multi-kinase inhibition across B-Raf V600E, EGFR, VEGFR-2, c-Met and Pim-1 with GI50 values spanning 0.33 to 4.87 micromolar on the NCI-60 panel, all while remaining non-lethal to cells at much higher concentrations.

The review also highlights a delivery innovation that may prove as consequential as any single molecule. Aljohani and colleagues encapsulated pyrazole and pyrimidine derivatives within chitosan-polyvinyl alcohol nanogels and observed dramatic potency gains: cytotoxicity improved by 31.82 percent against A549 lung cancer cells, 40.12 percent against HCT116 colon cells, 50.00 percent against HepG2 liver cells and 52.61 percent against MCF-7 breast cancer cells, while all formulations retained IC50 values above 48 micromolar against normal VERO cells. The compounds function as topoisomerase-II inhibitors and DNA intercalators, and the nanogel vehicle appears to overcome transport barriers that limit intracellular entry of the free molecules. This pairing of rational small-molecule design with polymeric formulation points toward a hybrid strategy in which scaffold optimization and delivery engineering advance in lockstep rather than in sequence.

Infectious disease and agriculture feature prominently in the new data as well. Zalaru’s team achieved minimum inhibitory concentrations of 0.023 micrograms per millilitre against Staphylococcus aureus, an extraordinary potency figure, without cytotoxicity toward normal fibroblasts. Alenazi and Alnoman’s pyrazole-thiazole hybrids showed broad-spectrum inhibition of S. aureus, E. coli and Candida albicans with MIC values as low as 3.125 micrograms per millilitre, occasionally surpassing standard antibiotics, while Saadon’s 5-hydroxy pyrazole carbothioamide suppressed bacterial biofilm formation by 96.17 percent, on par with gentamicin. Keerthi’s pyrazole-oxadiazole hybrids matched ethambutol against Mycobacterium tuberculosis H37Rv with an MIC of 1.56 micrograms per millilitre. On the agricultural side, Huang’s benzophenone-linked pyrazole carboxamides outperformed the commercial fungicide bixafen against Sclerotinia sclerotiorum with an EC50 of 4.11 micrograms per millilitre, and Chu’s sulfonamide-oxadiazole hybrids beat boscalid against Valsa mali, disrupting hyphal ultrastructure and plasma membrane integrity in ways that translated to effective protection of apple fruits in vivo.

Metabolic and inflammatory pipelines show equally disciplined structure-activity logic. Sura and colleagues coupled pyrazole to isatin-triazole spacers to produce DPP-4 inhibitors, with the lead compound achieving 87.95 percent enzyme inhibition at an IC50 of 1.56 nanomolar, comparable to sitagliptin and teneligliptin, through pi-pi stacking with TYR666 and PHE357 in the active cavity. Elgohary’s sulfonamide celecoxib analogues inhibited COX-2 at 0.05 micromolar and, in a formalin-induced paw edema model, reduced TNF-alpha by 71.43 percent and PGE2 by 77.11 percent, outperforming both celecoxib and indomethacin with normal liver, kidney and cardiac parameters. Feng’s neuroprotective pyrazoles suppressed IL-6 expression in stimulated microglial cells at 9.562 micromolar, exceeding dexamethasone and celecoxib, offering a candidate for the secondary inflammation that follows spinal cord injury. Akocak’s arylazo pyrazole carboxamides, meanwhile, inhibited acetylcholinesterase with a Ki of 20.86 nanomolar, nearly eight times more potent than the reference drug tacrine, suggesting relevance to neurodegenerative disease.

The review’s authors argue that the field is undergoing a paradigm shift away from classical single-target analogue synthesis toward intentional multi-target-directed ligands, and they identify several frontiers that will define the next generation of work. Emerging designs include 5-aminopyrazole inhibitors of the deubiquitinating enzyme USP7, which drive p53-mediated tumour suppression, and tetrasubstituted 5-arylamino pyrazoles that arrest endothelial cell migration and tube formation by modulating intracellular calcium, offering selective antiangiogenic profiles without blind systemic cytotoxicity. Hybridization with HDAC-inhibiting aminobenzamides is proposed as a route around drug-resistance mechanisms. Looking ahead, the authors advocate systematically pairing automated, AI-driven QSAR models with polymeric nano-formulations and targeted protein degradation technologies such as PROTACs, a combination they believe can carry the pyrazole scaffold from academic screens into optimized, low-toxicity clinical and field-ready candidates. For a ring first celebrated more than a century ago in antipyrine, the 2025-2026 literature makes a compelling case that its most productive era may be the one just beginning.

Subject of Research: Biological evaluation of novel bioactive pyrazole derivatives in medicinal chemistry and agrochemistry

Article Title: Recent biological evaluations of novel bioactive pyrazole derivatives developed between 2025 and 2026

Article References: Recent biological evaluations of novel bioactive pyrazole derivatives developed between 2025 and 2026. (n.d.). https://doi.org/10.1007/s44371-026-00966-1

Image Credits: AI Generated

DOI: 10.1007/s44371-026-00966-1

Keywords: pyrazole, medicinal chemistry, anticancer agents, EGFR inhibitors, COX-2 inhibitors, DPP-4 inhibitors, antimicrobial, agrochemicals, structure-activity relationships, drug discovery, nanogels, heterocyclic scaffolds